Brazilian researchers have published laboratory results showing that ultrasound waves can physically weaken certain viruses, including the flu and Covid-19 [1].
This development suggests a potential shift in how medical professionals approach viral infections. By using physical force rather than chemical compounds, scientists may find a way to deactivate pathogens without relying on traditional pharmaceutical drugs [2].
The findings, released in May 2026, were based on laboratory experiments conducted in Brazil [1, 2]. The research focused on the ability of ultrasound to disrupt the structural integrity of viral particles. By applying specific frequencies, the researchers observed that the viruses became fragile, which could theoretically prevent them from infecting host cells [1].
This approach targets the physical shell of the virus. Traditional antiviral medications typically work by blocking the replication process or preventing the virus from entering a cell through chemical interference [2]. In contrast, ultrasound aims to break the virus apart before it can function, a method that could potentially bypass the issue of drug resistance.
Despite the promising laboratory data, the technology is in its earliest stages. The researchers have not yet performed any tests on animals or humans [1]. Transitioning from a controlled petri dish environment to a living organism presents significant challenges, as ultrasound must be delivered to the site of infection without damaging surrounding healthy tissue [2].
The team is now looking for ways to refine the delivery of these waves. The goal is to create a therapeutic tool that is both safe for the patient and effective against a wide range of viral threats [1].
“Ultrasound waves can physically weaken certain viruses, including the flu and Covid-19.”
This research represents a move toward biophysical medicine, where mechanical energy is used as a primary treatment. While the lab results are a proof-of-concept, the lack of in vivo testing means this is not yet a viable clinical treatment. If successful in future human trials, it could provide a critical alternative for treating drug-resistant viral strains.
